Inside Precision Medicine June 12, 2024
A City of Hope-developed CAR T cell therapy has shown it is both safe and produced promising therapeutic activity in patients with metastatic castration resistant prostate cancer (mCRPC). Results of the Phase I clinical trial were published today in Nature Medicine.
The study treated 14 patients with prostate stem cell antigen (PSCA)-positive mCRPC patients with cancer that had spread beyond the prostate and no longer responded to hormone therapy. The CAR T cells were engineered in the lab of Saul Priceman, PhD, an associate professor in the department of hematology & hematopoietic cell transplantation at City of Hope. The team reprogrammed a patient’s immune cells to recognize and attack the PSCA protein found on the surface of cancer cells, which...
Today's Sponsors
Today's Sponsor